Evidence map›Paper›PMID 40268488›Full record

Trial reportBMJ open2025

HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial: a qualitative longitudinal study, South Africa.

Rujeko Samanthia Chimukuche, Londiwe Shandu, Silindile Zulu, Phindile Khanyile, Nishanta Singh, Zakir Gaffoor, Rachel Kawuma, Sheena McCormack, Janet Seeley, PrEPVacc Study Group

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04066881 (A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure Prophylaxis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04066881 phase2completednot on this map

A Phase IIb Three-arm, Two-stage HIV Prophylactic Vaccine Trial With a Second Randomisation to Compare TAF/FTC to TDF/FTC as Pre-exposure Prophylaxis

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2020 to 2024Enrolled1,512ConditionsHIV InfectionsArmsVaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Experimental PrEP:TAF/FTC once daily (weeks 0-26)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rujeko Samanthia ChimukucheAfrica Health Research Institute, Durban, KwaZulu-Natal, South Africa rujeko.chidawanyika@ahri.org.ORCID http://orcid.org/0000-0002-4890-2105
Londiwe ShanduAfrica Health Research Institute, Durban, KwaZulu-Natal, South Africa.
Silindile ZuluAfrica Health Research Institute, Durban, KwaZulu-Natal, South Africa.
Phindile KhanyileAfrica Health Research Institute, Durban, KwaZulu-Natal, South Africa.
Nishanta SinghHIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
Zakir GaffoorHIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
Rachel KawumaSocial Science, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.ORCID http://orcid.org/0000-0001-5338-3517
Sheena McCormackMRC Clinical Trials Unit, University College London, London, UK.
Janet SeeleyAfrica Health Research Institute, Durban, KwaZulu-Natal, South Africa.ORCID http://orcid.org/0000-0002-0583-5272
PrEPVacc Study Group

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionEnsuring the effectiveness of HIV prevention and treatment methods requires high levels of adherence. Studies have recognised the significance of trust in shaping HIV risk perception.

aimIn this qualitative analysis, our aim was to explore risk perceptions and understand how individuals assess and respond to HIV risks, as well as their uptake and adherence to oral pre-exposure prophylaxis (PrEP).

settingThe study was based on the setting of an HIV prevention trial conducted in South Africa.

methodsThirty individuals, 9% of the total clinical trial participants, enrolled in the clinical trial were purposively selected and interviewed at three time points within the trial during the follow-up phase. Data analysis was conducted using the Trust, Confidence and Cooperation framework that included constructs of trust, confidence and cooperation.

resultsThe findings show that the ongoing participation in the clinical trial played a significant role in influencing participants' decision to continue PrEP as HIV prevention. This decision was grounded in their trust that PrEP would effectively reduce their vulnerability to HIV and infection.

conclusionClear and consistent health-promoting initiatives enhance participants' self-awareness of HIV risks and promote understanding (uptake) and effectiveness of HIV prevention methods. TRIAL REGISTRATION NUMBER: NCT04066881.

Indexed as

Anti-HIV AgentsHealth Knowledge, Attitudes, PracticeHIV InfectionsMedication AdherencePre-Exposure ProphylaxisTrustAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedQualitative ResearchSouth AfricaYoung AdultAnti-HIV AgentsHealthHIV & AIDSPublic healthQUALITATIVE RESEARCH

Identifiers

PMID40268488
PMCPMC12020760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.